In the retina of mammals, dopamine (DA) is generally released by amacrine cells and is known to alter the physiology of most retinal cells. It is well known that DA reduces the amplitude of the b-wave of the electroretinogram (ERG) in rabbit. However, the specific receptor subtypes that mediate this action have not yet been elucidated. To do this, we recorded flash ERGs before and after the intravitreal injection of D 1 -like DA receptor agonists (SKF38393, A77693) and antagonist (SCH23390), and of D 2 -like agonist (R(À)-propylnorapomorphine hydrochloride; NPA) and antagonist ((S)-(À)-sulpiride). Contralateral control eyes were injected with the vehicle only. Both D 1 agonists provoked a reduction of the ERG b-wave amplitude (34.0% and 59.2% of the pre-injection level, respectively). The D 2 -like agonist NPA had no significant effects on ERG components. Unexpectedly, both D 1 -and D 2 -like antagonists also reduced the b-wave amplitude (28.9% and 59.8%). Overall, these data suggest that the previously described effect of DA on the rabbit ERG b-wave came from activation of D 1 -like receptors. On the basis of the effects observed with D 2 -like antagonist, a subtle contribution of D 2 -like presynaptic receptors cannot be ruled out.
Introduction
The retina of all mammals contains dopamine (DA). In most cases, including rabbits, this catecholamine is released by a sub-type of amacrine cells (Dowling & Ehinger, 1978) which are generally located in the proximal part of the inner nuclear layer and ramify extensively in one or more levels of the inner plexiform layer (Mitrofanis, Vigny, & Stone, 1988) . Five subtypes of dopaminergic receptors have been described and designated D 1 through D 5 . On the basis of their structure, binding properties, and intracellular action, these receptors can be grouped into two subfamilies: (1) the D 1 -like receptors (D 1 and D 5 ) which, when activated, stimulate adenylyl cyclase activity and cAMP formation; (2) the D 2 -like receptors (D 2 , D 3 , and D 4 ) which inhibit adenylyl cyclase. The activity of all neurons in the retina can be modulated by DA because they all exhibit D 1 -, D 2 -like or both receptor subfamilies. A number of studies have revealed the implication of DA in various forms of retinal processing such as light adaptation (Marshak, 2001 ) and horizontal cell coupling (He, Weiler, & Vaney, 2000) . Because of the latter action, DA is believed to modulate the center-surround antagonism of retinal receptive fields (Bodis-Wollner, 1996; BodisWollner & Tzelepi, 1998; Boumghar, Marois, Jolicoeur, & Casanova, 1997) . In rabbit, it has been shown that the intravitreal administration of DA (Gottvall & Textorius, 2003; Textorius, Nilsson, & Andersson, 1989 ) yields a reduction in the amplitude of the b-wave of the flash electroretinogram (ERG) (Jagadeesh & Sanchez, 1981) . Comparable results were obtained after the i.v. injection of apomorphine, which preferentially binds to D 2 -like receptors (Gao et al., 1990) . Our laboratory showed that the acute administration of apomorphine could induce a change in the contrast sensitivity of neurons in the lateral geniculate nucleus, i.e., the main thalamic target of ganglion cells (Boumghar et al., 1997) . Conversely, the destruction of the retinal DAergic network by the neurotoxin 6-hydroxydopamine (6-OHDA), was shown to increase the amplitude of the ERG b-wave (Lafond et al., 1994; Olivier, Jolicoeur, Lafond, Drumheller, & Brunette, 1986 .
Despite the bulk of neuroanatomical and physiological evidence showing that DA can modulate the activity of retinal cells in mammals, very little is known about the specific contribution of DA receptor subtypes in retinal functioning. While the observation that apomorphine mimics the effects of DA on the ERG suggests that D 2 -like receptors may subtend the retinal physiological impact of DA, the contribution of D 1 -like receptors cannot be ruled out because they present, depending of the enantiomer, substantial affinity to apomorphine (Baldessarini, Kula, Zong, & Neumeyer, 1994; De Keyser, De Backer, Wilczak, & Herroelen, 1995) . In the present study, we further investigated in vivo the contribution of D 1 -and D 2 -like receptors in the established DA-mediated reduction of the b-wave amplitude in rabbits. Parts of these findings have been presented in abstract form (Huppé-Gourgues, Coudé, & Casanova, 2002) .
Methods

Animal preparation
Experiments were carried out on 42 adult pigmented rabbits (2.5-3.5 kg) that were provided by the Université de Montréal animal facilities. Animals were treated according to the guidelines of the Canadian Council on Animal Care. A 12 h light/dark cycle was used to maintain the animals in a normal day-night cycle. All procedures described below started in the morning to minimize any influence of the circadian cycle. Atravet (0.5 mg kg À1 ) and atropine (0.1 mg kg À1 ) were administrated to the animal 30 minutes before general anesthesia that was induced by urethane (1.5 g kg À1 i.v.) (Sigma-Aldrich), administered via the marginal vein of the ear. All surgical wounds and pressure points were infused with a local anesthetic (Lidocaine hydrochloride 2%). Heart rate and O 2 blood saturation were constantly monitored with an oxymeter (Nonin). A tracheotomy was performed. Deep tendon reflexes were checked to ensure a satisfactory level of anesthesia during the surgery. The animal was then placed in a stereotaxic frame and muscular relaxation was obtained by injecting gallamine triethiodide (10 mg kg À1 h À1 , i.v.) mixed in dextrose ringer (5%). The animal was then artificially ventilated (N 2 O/O 2 : 70/30% plus halothane 0.5-1%). End-tidal CO 2 level was maintained between 28 and 32 mmHg by adjusting the stroke volume and respiratory rate. The electrocardiogram was continuously monitored, and the core temperature was maintained at 37-38°C by a feedback-controlled heating pad placed under the animal. Pupils were dilated with isopto-atropine (1%) and nictitating membranes were retracted with local application of phenylephrine hydrochloride (2.5%). The corneas were protected from desiccation by applying artificial tears (carboxyl methylcellulose).
Recordings
ERG-Jet contact lens electrodes (Universo S.A., Switzerland) were placed on the cornea of the two eyes. Two subdermal electrodes were positioned on the bridge of the nose and between the ears on the top of the skull and served as ground and reference, respectively. Given that DAergic substances can have an effect on pupil dilation (e.g. Corbett, Buckley, & Richards, 1994) and that the testing period lasted for several hours, artificial pupils of 6 mm were used in some experiments. In these cases, the ERG was recorded with a DTL fiber (Hébert, Vaegan, & Lachapelle, 1999) . No differences were noted between the effects of a given ligand on the ERG whether artificial pupils or regular jet electrodes were used. Moreover, casual observation of the pupil did not reveal any significant changes of its diameter during the testing periods.
Signals were amplified 5000· (P511, Grass, West Warwick, RI) and band-pass filtered between 1 and 1000 Hz. Signals were then fed to an analogue-digital interface (1401plus, CED, Cambridge, UK) and were acquired using the software Signal (v.2.0x, CED, Cambridge UK). A custom loop program allowed us to record ERGs at exactly 15 min apart for the whole duration of the experimental procedure. To provide a more uniform stimulation (Ganzfeld-like stimulation) of the retina, ping-pong balls cut in half covered the eyes.
Visual stimulation
Visual stimulation consisted of a series of stroboscopic flashes (single flash duration of 10 ls) of different frequencies and intensities generated by a photic stimulator PS33plus (Grass Instruments Co., West Warwick, RI). The flash lamp was placed 45 cm above the animalÕs head to allow for the simultaneous stimulation of the two eyes. For each animal, the effects of the DA ligands on the ERG were studied in the two luminance conditions defined in the ISECV standards (Marmor & Zrenner, 1998) , and in a third intermediate condition. In scotopic conditions, flashes were presented at a frequency (f) of 0.1 Hz, and at an intensity (i) of 0.1 cd m À2 s, the background luminance (bl) being at 0 cd m À2 . In this condition, each ERG waveform represents an average of five responses. In photopic conditions (i = 3 cd m À2 s, bl = 30 cd m À2 ), flashes of 1 Hz were used, and each ERG consisted of an average of 30 responses. In the intermediate condition in which both rods and cones contribute to vision (namely mesopic), parameters were set at: f = 0.5 Hz, i = 2 cd m À2 s and bl = 13 cd m À2 . Background illumination corresponded to the room illumination by tungsten lamps (3200 K). Responses were averaged 15 times. All luminance values were obtained at the level of the animalÕs eye with a photometer.
Dopaminergic agents
The active substances used to characterize the contribution of D 1 -like receptor subtypes were the agonists 
. For clarity, the terms SKF-38393, A-77636, SCH-23390, NPA, and sulpiride will be used throughout. The ligands were dissolved in sterile water, with the exception of sulpiride which was dissolved in 0.1 N HCl. Concentrations used varied from 1 to 0.00001 mg in the injection volume of 100 ll. All solutions had a pH of $7, with the exception of sulpuride-HCl and HCl-vehicle solutions for which the pH was $1.5 in both cases. Injections were made in the vitreous humor i.e., a volume of $1.4 ml; (Green, Leopold, & Sawyer, 1957) by inserting a 30G G needle (Becton Dickinson and Co, Franklin Lakes, NJ) attached to a 250 ll Hamilton syringe throughout the sclera, 2-3 mm caudal to the limbus.
Experimental protocol
After a 1 h period of adaptation to the lightning conditions, binocular ERGs were recorded every 15 min for a control period of 2 h. This was done to determine baseline amplitude of the ERG components of the two eyes (normalized response). The DAergic agent was then injected intravitreally into the test eye (T0), and vehicle (i.e., sterile water in all cases, except for Sulpiride experiments, in which the HCl solution was used) was injected into the control eye. Recordings were then made every 15 min after the injection. Flashes were interrupted between each recording session, and the animal was kept in the background illumination condition used in the given protocol. In general, recordings lasted 5 h after the drug administration, but could be prolonged up to 24 h. In general, after recovery, a second injection protocol was initiated with the same animal, in identical lighting conditions. The former control eye was then used as the test eye, and vice-versa, and the same drug was injected. Therefore the n values provided throughout represent the actual number of injections.
Once the last recording was made, the animal was killed with an i.v. injection of about 1.5 ml of pentobarbital sodium (Euthanyl 110 mg kg À1 ). Eyeballs were removed and dissected for a gross evaluation of any trauma resulting from the injection procedure, and particularly to verify that no structure (e.g. lens) was inadvertently nicked by the needle.
We measured time-to-peak and amplitude just before, and at predetermined time intervals after, the injection of test agents. Post-injection b-wave amplitudes were expressed as percent of pre-injection amplitudes. In addition, the amplitude computed at each hour post-injection was statistically compared to that recorded from the control eye. The b-wave of the latter was never significantly modified throughout the recording session. Statistical significance ( p 6 0.05) was determined with paired t-test, oneway ANOVA for parametric data and Kruskall-Wallis and Wilcoxon test for non-parametric data.
Results
D 1 -like receptor contribution to the b-wave amplitude
The intravitreal injection of the D 1 -like agonist SKF38393 reduced the amplitude of the ERG signal. A representative example is shown in Fig. 1 . SKF38393 reduced the b-wave amplitude by 30%, while the latency of the waveform remained constant at 82.3 ± 0.3 ms (panel A, upper traces). The vehicle alone did not modify the ERG of the control eye (bottom traces). Panel B represents the time course of the action of the agonist. The maximal SKF38393-induced reduction was observed between 1 and 2 h post-injection. A recovery was apparent 4 h after injection and was virtually completed after 7 h (see also the upper-right ERG waveform in panel A). Panel B also shows the lack of changes of the ERG b-wave amplitude for the control eye throughout the recording period. Pooled data from 24 SKF38393 injections were normalized and results are shown in panel C of Fig. 1 (a significant effect was observed in 23 out of the 24 injections. In this and all subsequent cases, data from all injections were used for statistical analysis). The maximum inhibitory effect of the DA agonist was observed 2 h postinjection, with a mean reduction of 34.0% ± 4.1% (t paired = À3.66, p = 0.001). The difference in b-wave amplitude between SKF38393 and control eyes returned to control values 7 h post-injection (t paired = À1.94, p = 0.06). The action of SKF38393 (1 mg (100 ll) À1 ) on the ERG b-wave was comparable in all conditions of illumination (oneway ANOVA, f (22,2) = 1.51, p = 0.24). The reduction of the b-wave amplitude was 26.8% ± 8.0% (n = 6), 45% ± 6.8% (n = 10), and 34.6 ± 5.1% (n = 9) in photopic, mesopic, and scotopic conditions, respectively.
Two SKF38393 doses were used in the study, 0.1 and 1 mg (100 ll) À1 . When compared to the vehicle, the low concentration yielded a mean decrease of 20.3% ± 6.1% (n = 6) of the b-wave amplitude, while the high concentration led to a reduction of 34.0% ± 4.1% (n = 24). Even if only two doses were studied, the effect of SKF38393 appears to be dose-dependent since a higher concentration of the agonist yielded a more pronounced reduction of the b-wave (Kruskal-Wallis, p = 0.0001). Only the 1 mg (100 ll)
À1 dose produced an effect that was statistically significant (t paired = À3.66, p = 0.001).
The D 1 -like receptor agonist A77636 had a stronger effect on the b-wave than SKF38393. Three representative examples are shown in Fig. 2 . Panel A presents the effect of A77636 at a dose of 1 mg (100 ll) À1 in the mesopic lighting condition (filled symbol). The agonist considerably reduced the b-wave amplitude 8 h post-injection (decrease of 60% from pre-injection recordings), whereas the vehicle had no effect in the control eye (open symbol). As illustrated, no recovery of the b-wave was observed at this dose of A77636. This observation stands for all five injections made at 1 mg despite the fact that post-injection recordings lasted up to 18 h. In all five cases the b-wave decrease was significant (Wilcoxon, p = 0.043) 2 h after the drug administration, and reached a value of 60.3 ± 4.6% after 10 h. Panel B shows the action of A77636 administered at 0.5 mg (100 ll)
À1 . In this case, the reduction of the b-wave was of 51.0% after 3 h. When considering all four injections at this dose, A77636 produced a reduction of 43.0% ± 6.5% of the b-wave amplitude after 3 h. Two out of four injections recovered after 10 h, the two others failed to recover. Finally, A77636 was injected at a low concentration of 0.2 mg (100 ll) À1 in one animal (n = 2). In both cases, the agonist failed to modify the amplitude of the ERG (see panel C). ) and of the vehicle were pooled together and normalized. A significant decrease was observed during 2 h post-injection. One hundred percent level represents the mean amplitude before injection. Error bars represent SEM. In this and all figures: * = p < 0.1, ** = p < 0.05, *** = p < 0.001.
Blocking the D 1 -like receptors with the antagonist SCH23390 (1 mg (100 ll) À1 ) also produced a reduction of 28.9% ± 8.8% of the b-wave amplitude 3 h post-injection in the mesopic condition (panel A of Fig. 3 ). The amplitude of the b-wave was significantly different from that of the control eye 1 h after injection (Wilcoxon, p = 0.028) and the reduction in signal amplitude lasted for the next 6 h. A significant effect of SCH23390 on the b-wave amplitude was observed in four out of six injections.
D 2 -like receptor contribution to b-wave amplitude
Injections of the D 2 -like receptor agonist NPA failed to produce any significant changes in the b-wave amplitude. Panel A of Fig. 4 shows the outcome of twelve injections: clearly, there was no significant difference between the b-wave amplitude of the NPA-treated and normal eye up to 10 h after the injections. Increasing or decreasing the NPA concentration yielded comparable findings. This is illustrated in panel B of Fig. 4 . Varying the dose from 0.0001 to 1 mg (100 ll) À1 failed to produce any significant changes in the waveform amplitude (1 mg (100 ll)
À1
, mean reduction of the b-wave 27% ± 1.8%, n = 9; 0.1 mg (100 ll)
, 20.4 ± 6.5%, n = 8; 0.01 mg(100 ll) À1 , 16.7%, n = 1; 0.001 mg (100 ll)
, 22.0 ± 1.6%, n = 4; 0.0001 mg (100 ll)
, À0.08 ± 1.8%, n = 3) (KruskalWallis, p = 0.12). Similarly, changing the background luminance did not reveal any notable physiological impact of NPA (Kruskal-Wallis, p = 0.73). The numbers of injections of NPA 1 mg (100 ll) À1 in the photopic, mesopic and scotopic conditions were respectively 4, 4, and 1. A different picture emerged when the D 2 -like receptor antagonist sulpiride was administered (panel B of Fig. 3 ). This ligand reduced the b-wave amplitude for more than 15 h. The maximum effect was seen 6 h post-injection and the b-wave amplitude was reduced to 59.8 ± 4.6% of the original amplitude (Wilcoxon, p = 0.018).
Discussion
The present findings indicate that retinal activity, as measured with the b-wave of the electroretinogram, is mainly modulated by the activation of D 1 -like rather than D 2 -like receptors. There was no relationship between the observed changes and the various luminance conditions in which the testing was done, suggesting that the effective ligands studied here were not specific to the rod or cone pathways of the retina.
The D 1 -like receptor agonists SKF38393 and A77636 produced a significant reduction in the amplitude of the b-wave, but not of the a-wave (data not shown). A similar modulation of the ERG was reported by Textorius et al. (1989) who demonstrated that DA provoked a decrease of the ERG b-wave in a rabbit in vivo eye cup preparation. Comparable findings were described after the systemic administration of apomorphine in the same animal model (Jagadeesh & Sanchez, 1981) . To our knowledge, only one study previously investigated the impact of SKF38393 on retinal evoked potentials. In rabbits, Marmor et al. (1988) reported that an intramuscular injection SKF38393 had very little inhibitory effect on the b-wave amplitude and oscillatory potentials. The fact that they observed a more subtle effect than ours is likely due to the difference in the mode of administration of the ligand (intramuscular vs. intravitreal). We are not aware of any study reporting the effect of the agonist A77636 on retinal function. On the basis of its long-lasting action on the b-wave amplitude, this ligand appears to be more potent then SKF 38393 at similar doses. Our findings that D 1 -like agonist can modulate the amplitude of the ERG b-wave are further substantiated by the observation that, in monkey, the administration of the D 1 -like agonist cy208-243 reduces the pattern ERG at low spatial frequencies (Peppe, Antal, Tagliati, Stanzione, & Bodis-Wollner, 1998) . The mechanisms by which the D 1 -like agonists used in the present study affect the ERG remain to be determined. It is generally accepted that the b-wave reflects the K + -mediated depolarization of Mü ller cells (Newman & Odette, 1984; Wen & Oakley, 1990; Xu & Karwoski, 1994) even though there is mounting evidence that depolarizing ON bipolar cells may also directly contribute to the waveform (Green & Kapousta-Bruneau, 1999; Stockton & Slaughter, 1989) . Both cell types contain D 1 -like receptors (Nguyen-Legros et al., 1987; Nguyen-Legros, Simon, Caille, & Bloch, 1997; Veruki & Wässle, 1996) and may therefore contribute to the effects of the D 1 -like agonists.
While the administration of D 1 -like agonists induced a decrease of the ERG b-wave, the D 2 -like agonist studied here (R(À)-NPA; affinity 100-to 425-fold greater than for D 1 -like receptors, Baldessarini et al., 1994; Gao et al., 1990) failed to produce a significant change in the amplitude of the ERG. This is somewhat surprising given that apomorphine, a D 2 -like agonist, is known to reduce the amplitude of the ERG b-wave. Recent studies showed that apomorphine has a greater affinity for D 2 than D 1 -like receptors 2.6-to 22-fold depending on the enantiomer 1 and nature of the non-retinal brain tissue studied (Baldessarini et al., 1994; De Keyser et al., 1995; Gao et al., 1990) . One explanation would be that, in the retina, apomorphine binds preferentially to D 1 -like receptors. Another explanation would be that NPA may not target receptors coupled with b-wave mechanisms. This latter suggestion is however unlikely because Mü ller cells, which are implicated in b-wave genesis, possess D 2 receptors (Biedermann, Frohlich, Grosche, Wagner, & Reichenbach, 1995;  in the guinea pig retina). If present in rabbits, it is possible that activation of these receptors yielded subtle changes that may not be seen at the level of a gross retinal response such as the ERG, or simply that NPA acts on D 2 -like receptors other than the kind Mü ller cells express (e.g. D 4 ). Another possibility may come from the fact that the presynaptic autoreceptors are of the D 2 -like type. Activation of the autoreceptors would reduce the synthesis and release of the endogenous DA which normally binds to both D 1 -and D 2 -like receptors (Stanzione et al., 1999) , thus masking any strong effect of the ligand. NPA could have a dual action, inhibiting DA-release through the D 2 -like autoreceptors but simultaneously activating b-wave reduction through postsynaptic D 1 -like receptors. Although not statistically significant, the reduction in b-wave amplitude by NPA at all but the lowest dose (Fig. 4B) is consistent with the last assumption, i.e. the D 2 -like effect outweighing the D 1 -like effect.
Overall, given the high affinity of the DA agonists SKF38393 and A77636 that we used for the D 1 -like receptors (150-and 30-to 750-fold greater for D 1 -like receptors, respectively; Kebabian et al., 1992; Seeman & Van Tol, 1994) , the results of the present study strongly suggest that the effect of DA on the ERG described by Jagadeesh and Sanchez (1981) and Textorius et al. (1989) was most likely mediated through activation of D 1 -like receptors.
The intravitreal injection of the D 1 -like antagonist SCH23390 (affinity: 5500-fold; (Seeman & Van Tol, 1994) ) produced a significant reduction of the b-wave amplitude, but less pronounced than that induced by the agonist SKF38393. This result was unexpected. Indeed, blocking the D 1 -like receptors should yield a reduction of the sites available for DA, therefore mimicking a decrease of DA content. This decrease would then yield an increase of the b-wave amplitude (Lafond et al., 1994; Olivier et al., 1986; Olivier et al., 1987) . Marmor et al. (1988) found the same contradictory effect in rabbits as they reported that the intramuscular injection of both SCH23390 and SKF38393 reduced the b-wave amplitude. Other laboratories also found that D 1 antagonists can modulate retinal responses. Wioland, Rudolf, and Bonaventure (1990) showed that haloperidol, a mixed D 1 -and D 2 -like antagonist, reduced the b-wave amplitude of the chicken retina in photopic condition. In the isolated, arterially perfused eye of the cat, the D 1 -like antagonist fluphenazine provoked an opposite effect, i.e. an enhancement of the b-wave (Schneider & Zrenner, 1991) . In the present study, SCH23390 was administered at a single dose of 1 mg (100 ll) À1 . It may be possible that at this dose, the ligand exhibits some neurotoxicity. This assumption however can hardly be reconciled with the fact that there was a recovery of the ERG waveform following the antagonistÕs administration. Another option is that SCH23390 exerted its action via non-DA receptors. For example, it has been reported that NPA not only has affinity for D 1 -and D 2 -like receptors but also for alpha-2 adrenoreceptors (Baldessarini et al., 1994) . Clearly, the mechanisms by which SCH23390 can modify the retinal function remain to be determined.
While the D 2 -like agonist NPA had no significant effect on the ERG, the antagonist S-sulpiride (affinity 3000-fold for D 2 -compared to D 1 -like receptors, (Seeman & Van Tol, 1994) ) provoked a long-lasting reduction of the b-wave amplitude. Again, other studies revealed that D 2 -like antagonists can alter retinal physiology. In rabbits, Jagadeesh, Lee, and Salazar-Bookaman (1980) reported that the intravenous injection of chlorpromazine increased the amplitude of the b-wave. This effect is opposite to that described in the present study. It may be due to differences in the mode of administration or in the specificity of the two agents at different receptor subtypes. In cats, the administration of sulpiride induced an increase of the b-wave amplitude in scotopic conditions (Schneider & Zrenner, 1991) . This is contrary to our findings and the difference may again come from inter-species differences or from the distinct experimental approach (in vivo vs. isolated eye preparation). It is possible that the reduction of b-wave amplitude that was observed here after the administration of sulpiride may be mediated through the DA autoreceptors. Blocking the presynaptic autoreceptors could raise the synthesis and release of the endogenous DA, and the released DA could then activate both postsynaptic D 1 -and D 2 -like receptors.
In conclusion, our data further support the involvement of DA in the modulation of retinal function. They showed that the dopaminergic impact on the ERG b-wave is largely mediated by D 1 -like receptors, suggesting that the latter are preferentially involved in the transmission of information within the inner and middle parts of the retina. Since none of the agonists used here has an exclusive affinity for D 1 -or D 2 -like receptors, and that D 2 -like antagonist can alter the amplitude of the b-wave, we cannot rule out any subtle contribution of D 2 -like receptors in the dopaminergic modulation of the ERG.
